SCHEMBL2396737

SCHEMBL2396737

CCOC(=O)c1cn(Cc2ccc(Br)cc2)c2c(c1=O)C(=O)CCC2

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
PDE3B Q13370 5/20 0.48
PDE3A Q14432 5/20 0.48
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 2/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
P2RX3 P56373 1/20 0.40
BRD4 O60885 1/20 0.39
P2RX7 Q99572 1/20 0.38
HTT P42858 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397287 0.88 HDAC1 (0.48) HDAC1HDAC6PDE3BPDE3AKDM4E
SCHEMBL11393782 0.83 KDM4E (0.48) KDM4ESMN1; SMN2LMNAALDH1A1TP53
SCHEMBL2396693 0.81 PDE3B (0.46) HDAC1HDAC6PDE3BPDE3AKDM4E
SCHEMBL2394921 0.79 ALDH1A1 (0.43) HDAC1HDAC6PDE3BPDE3AKDM4E
SCHEMBL2394918 0.79 ALDH1A1 (0.43) HDAC1HDAC6PDE3BPDE3AKDM4E
SCHEMBL16341783 0.74 CNR2 (0.63) LMNATP53P2RX3
SCHEMBL1666185 0.73 CHRM1 (0.44) KDM4ESMN1; SMN2ALDH1A1TP53HPGD
SCHEMBL8010027 0.73 CHRM1 (0.56) HDAC1HDAC6LMNA
SCHEMBL6497082 0.72 ALDH1A1 (0.42) HDAC1HDAC6PDE3BPDE3AKDM4E
SCHEMBL2396332 0.72 KMT2A (0.40) PDE3BPDE3AKDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252299-B1 FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-03-19 EP disclosed
US-8022215-B2 Fused pyridone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2011-09-20 US disclosed
US-20100324088-A1 Fused Pyridone M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME CORP. (US) 2010-12-23 US disclosed
EP-2252299-A1 FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2010-11-24 EP disclosed
WO-2009102588-A1 FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK & CO., INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324088-A1 Fused Pyridone M1 Receptor Positive Allosteric Modulators CHRM1, CHRM2, CHRM4 HDAC1 1696/4885HDAC6 4362/4885PDE3B 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.